Dong-A Mulls Fresh Options After Allergan Ends Evogliptin Deal
Executive Summary
With Allergan handing back the global development and sales rights of evogliptin as a NASH therapy to Dong-A, the South Korean firm is now considering an alternative business model around the DPP-4 inhibitor.
You may also be interested in...
Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals
Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.
Tobira, Dong-A Stick To NASH Plans Despite CENTAUR Results
The failure of Tobira's cenicriviroc to meet its primary endpoint in the CENTAUR study has raised some concerns in South Korea over the prospects for a combo therapy with Dong-A ST's evogliptin. But the two firms are sticking to their clinical development plans based on the positive secondary endpoint outcome in the study.
Large-Scale Funding Rises In Korea Amid Biotech Investment Boom
After record venture capital activity around South Korean biotechs last year, the strong investment interest has persisted so far this year, with an increased number of companies receiving large-scale funding as the promising sector emerges amid the pandemic.